University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Peter R. Carroll, MD, MPH

Peter R. Carroll, MD, MPH

Associate Director, Strategic Planning and Clinical Services; and Program Leader, Prostate Cancer Program, Helen Diller Family Comprehensive Cancer Center; Associate Dean, School of Medicine; Chair, Department of Urology, UCSF
Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer; Taube Family Distinguished Professorship in Urology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

My main research interests include identifying clinical and pathologic determinants of prostate cancer recurrence, progression, and mortality; discovering novel biomarkers for prostate cancer diagnostics and prognostics; developing evidence-based guidelines for improved management of prostate cancer patients; and examining the impact of lifestyle on health-related quality of life and survivorship among men with prostate cancer. Since 1995, I have been PI of CaPSURE™, a national disease registry study of over 14,000 men with prostate cancer treated at 40+ sites. At UCSF, we have developed a novel program in clinical management of and research on active surveillance for men with low-burden prostate cancer. We are committed to reducing the burden of prostate cancer treatment (physical, psychological and monetary). In 2007, I and colleagues initiated the Prostate Cancer Active Surveillance Study (PASS), a large multi-institutional cohort of men on active surveillance, designed to examine quantitative metabolic, molecular, and physiologic imaging biomarkers and lifestyle factors as novel predictors of prostate cancer progression. We aim to better determine which patients may safely avoid radical treatment, while concurrently identifying men who may benefit from early treatment instead of active surveillance.

Education

University of California, Berkeley, BA, 1974, Zoology
Georgetown University School of Medicine, Washington, D.C., MD, 1979, Medicine
University of California, Berkeley, MPH, 2008
 


Professional Experience

  • 1984-1986
    Fellow, Urology Service, Memorial Sloan-Kettering Cancer Center
  • 1986-1992
    Assistant Professor in Residence, Dept. of Urology, University of California, S.F
  • 1992-1993
    Associate Professor, Dept. of Urology, University of California, San Francisco
  • 1996-present
    Program Leader, Program in Urologic Oncology, UCSF Cancer Center
  • 1996-present
    Professor and Chair, Department of Urology, UCSF, San Francisco, CA
  • 2003-present
    Surgeon-in-Chief, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2006-present
    Associate Director of Clinical Services and Strategic Planning, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2006-present
    Associate Dean, UCSF School of Medicine

Honors & Awards

  • Other Experience and Professional Memberships
  • 2002-present
    American Urological Association, Prize Essay Committee (Chair)
  • 2002-2008
    American Urological Association, Update Series Advisory Committee (member)
  • 2001-present
    American Board of Urology, Trustee, President Elect (2006-2008)
  • 2001-present
    American College of Surgeons Commission on Cancer, AUA representative
  • 2000-present
    American Association of Genitourinary Surgeons, Site Committee
  • 2003-present
    American Association of Genitourinary Surgeons, Councilor
  • 2004-present
    ASCO Prostate Cancer Committee, Symposium Committee
  • 2004-present
    ASCO, Oncology Taskforce
  • 2005-present
    ASCO, Cancer Communications Committee, Roster of Cancer Experts
  • 2005-present
    American College of Radiology’s Appropriateness Criteria Expert Panel on Radiation Oncology-Prostate, AUA representative
  • 2006-present
    The Journal of Urology, Associate Editor
  • 2011 – present
    AUA Update, Editor
  • Honors:
  • 2001
    Ken and Donna Derr - Chevron Endowed Chair in Prostate Cancer
  • 2002
    Clinical Society of the American Association of Genitourinary Surgeons
  • 2004
    Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer
  • 2010
    AUA Eugene Fuller Triennial Prostate Award
  • 2010
    Society of Urologic Oncology Medal
  • 2014
    Barringer Medal, American Association of Genitourinary Surgeons

Selected Publications

  1. Carroll PR, Parsons JK. Guidelines should be assessed based on the underlying evidence. CMAJ. 2019 Aug 06; 191(31):E871.
    View on PubMed
  2. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. Reply by Authors. J Urol. 2019 Jul 31; 10109701JU00005793126115939.
    View on PubMed
  3. Bauer SR, Carroll PR, Grady D. Hematuria Practice Guidelines That Explicitly Consider Harms and Costs. JAMA Intern Med. 2019 Jul 29.
    View on PubMed
  4. Jeong CW, Cowan JE, Broering JM, Ten Ham RMT, Wilson LS, Carroll PR, Cooperberg MR. Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry. Eur Urol. 2019 Jul 22.
    View on PubMed
  5. Odisho AY, Bridge M, Webb M, Ameli N, Eapen RS, Stauf F, Cowan JE, Washington SL, Herlemann A, Carroll PR, Cooperberg MR. Automating the Capture of Structured Pathology Data for Prostate Cancer Clinical Care and Research. JCO Clin Cancer Inform. 2019 Jul; 3:1-8.
    View on PubMed
  6. Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Kobayashi Y, Simko J, Farrokhian N, Lindquist K, Greene S, Ontiveros P, Graf R, Rodriquez A, Suraneni M, Wang Y, Landers M, Carroll P, Cooperberg MR, Dittamore R, Paris PL. Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy for Clinically Localized, High - Risk Prostate Cancer. J Urol. 2019 Jun 19; 101097JU0000000000000393.
    View on PubMed
  7. Balakrishnan AS, Nguyen HG, Shinohara K, Au Yeung R, Carroll PR, Odisho AY. A Mobile Health Intervention for Prostate Biopsy Patients Reduces Appointment Cancellations: Cohort Study. J Med Internet Res. 2019 Jun 02; 21(6):e14094.
    View on PubMed
  8. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. Study of Prostate Ablation Related Energy Devices (SPARED) Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. J Urol. 2019 May 30; 101097JU0000000000000357.
    View on PubMed
  9. Balakrishnan AS, Zhao S, Cowan JE, Broering JM, Cooperberg MR, Carroll PR. Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 2019 May 28.
    View on PubMed
  10. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 May 23.
    View on PubMed
  11. Westphalen AC, Fazel F, Nguyen H, Cabarrus M, Hanley-Knutson K, Shinohara K, Carroll PR. Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions. Int Braz J Urol. 2019 May 15; 45.
    View on PubMed
  12. Zuniga KB, Zhao S, Kenfield SA, Cedars B, Cowan JE, Van Blarigan EL, Broering JM, Carroll PR, Chan JM. Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer. J Urol. 2019 May 15; 101097JU0000000000000336.
    View on PubMed
  13. Lawhn-Heath C, Flavell RR, Behr SC, Yohannan T, Greene KL, Feng F, Carroll PR, Hope TA. Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer. AJR Am J Roentgenol. 2019 Apr 30; 1-8.
    View on PubMed
  14. Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance. J Urol. 2019 Apr 26; 101097JU0000000000000290.
    View on PubMed
  15. Balakrishnan AS, Cowan JE, Cooperberg MR, Shinohara K, Nguyen HG, Carroll PR. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance. J Urol. 2019 Apr 08; 101097JU0000000000000247.
    View on PubMed
  16. Cedars BE, Washington SL, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance of Early Stage Prostate Cancer. J Urol. 2019 Apr 08; 101097JU0000000000000271.
    View on PubMed
  17. Carroll P, Schmidt B. Editorial Comment. J Urol. 2019 04; 201(4):820.
    View on PubMed
  18. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Mar 28.
    View on PubMed
  19. Boreta L, Gadzinski AJ, Wu SY, Xu M, Greene K, Quanstrom K, Nguyen HG, Carroll PR, Hope TA, Feng FY. Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy. Urology. 2019 Mar 27.
    View on PubMed
  20. Tang J, Zhong L, Paoli C, Paciorek A, Carroll P, Wilson L. Longitudinal Comparison of Patient-Level Outcomes and Costs Across Prostate Cancer Treatments With Urinary Problems. Am J Mens Health. 2019 Mar-Apr; 13(2):1557988319835326.
    View on PubMed

Go to UCSF Profiles, powered by CTSI